Corona Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.30 Cr
as on 17-11-2024
- Paid Up Capital ₹ 7.67 M
as on 17-11-2024
- Company Age 16 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.14 Cr
as on 17-11-2024
- Satisfied Charges ₹ 9.50 M
as on 17-11-2024
- Revenue 0.38%
(FY 2023)
- Profit 159.79%
(FY 2023)
- Ebitda 20.57%
(FY 2023)
- Net Worth 4.45%
(FY 2023)
- Total Assets 10.95%
(FY 2023)
About Corona Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.30 Cr and a paid-up capital of Rs 7.67 M.
The company currently has active open charges totaling ₹2.14 Cr. The company has closed loans amounting to ₹9.50 M, as per Ministry of Corporate Affairs (MCA) records.
Babita Dixit, Satanshu Mathur, and Vivek Khandelwal serve as directors at the Company.
- CIN/LLPIN
U85100UR2008PTC032700
- Company No.
032700
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Sep 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Udham Singh Nagar, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Corona Pharmaceuticals Private Limited. offer?
Corona Pharmaceuticals Private Limited. offers a wide range of products and services, including Antipyretic Medication, Dolo Tablets, Multivitamin Tablets & Capsules, Pharmaceutical Syrup, Multivitamin Syrup & Drops.
Who are the key members and board of directors at Corona Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Babita Dixit  | Additional Director | 01-Apr-2021 | Current |
| Satanshu Mathur | Director | 10-Dec-2008 | Current |
| Vivek Khandelwal | Director | 31-Jul-2023 | Current |
Financial Performance of Corona Pharmaceuticals.
Corona Pharmaceuticals Private Limited., for the financial year ended 2023, experienced modest growth in revenue, with a 0.38% increase. The company also saw a substantial improvement in profitability, with a 159.79% increase in profit. The company's net worth moved up by a moderate rise of 4.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Corona Pharmaceuticals?
In 2023, Corona Pharmaceuticals had a public holding of 85.62%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Khandelwal Hospital And Urology Centre Private LimitedActive 7 years 6 monthsVivek Khandelwal is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 14 Aug 2023 | ₹1.40 M | Open |
Others Creation Date: 30 Jun 2022 | ₹2.00 Cr | Open |
Others Creation Date: 06 Jul 2018 | ₹9.50 M | Satisfied |
How Many Employees Work at Corona Pharmaceuticals?
Corona Pharmaceuticals has a workforce of 48 employees as of Aug 12, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Corona Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Corona Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
